Auf dieser Seite
NEO NeoGenomics, Inc. - Common Stock
NASDAQ · Health Care · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Jul 28, 2026
$18,47
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$7,0752-Wochen-Tief
$20,0552-Wochen-Hoch
Marktkapitalisierung (MRQ)
$2.36B
P/E
-77.9
Umsatz
$727M
Ihre Abzeichen
52W-Spanne
$7–$20
Analystenbewertung
BUY
Kursziel
$20
P/E
-77.9
ROE
-12.8%
Nettogewinnmarge
-6.8%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
NEO Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$18.47
Marktkapitalisierung (MRQ)
$2.36B
P/E
-77.9
Umsatz
$727M
ROE
-12.8%
Verschuldungsgrad (MRQ)
0.5
52W-Spanne
$7–$20
NEO Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Über NeoGenomics, Inc. - Common Stock Unternehmensübersicht von Wikipedia
NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.
Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US, with laboratories in Florida, California, Tennessee, and Texas.
## History
NeoGenomics first received state and national-level laboratory certifications in 2002. Three years later in 2005, the company developed a technical-only service model using FISH.
In 2013, the company launched its sequencing platform and was listed on the Nasdaq Stock Market as NEO. In 2014, NeoGenomics launched molecular tests including BTK and CALR mutation analysis.
In 2015, NeoGenomics acquired Clarient, Inc. and its subsidiary company, Clarient Diagnostic Services, Inc., a national cancer diagnostics laboratory with capabilities in immunohistochemistry for solid tumor cancers from GE Healthcare. Clarient is headquartered in Aliso Viejo, California; with an ancillary laboratory in Houston, Texas.
In November 2017, NeoGenomics established their first headquarters outside the United States in Rolle, Switzerland.
In September 2024, the District Court for the Middle District of North Carolina entered a permanent injunction against NeoGenomics’ accused RaDaR assay, which was preliminarily enjoined in December 2023.
Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
SektorHealth Care
BrancheHealth Care
Mitarbeiter2.500
LandUS
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$727M2016-12-31 → 2025-12-31
Freier Cashflow$-22M2017-12-31 → 2025-12-31
Nettogewinnmarge-6.8%2019-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | NEO | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E | -77.95-Jahres-Durchschnitt ≈-73.2 | ≈-73.2 | · | · | |
| P/S (TTM) | 3.15-Jahres-Durchschnitt ≈3.8 | ≈3.8 | 1.1 | Überbewertet | |
| K/B (MRQ) | 3.05-Jahres-Durchschnitt ≈2.2 | ≈2.2 | 2.4 | Fairer Wert | |
| EV / EBITDA | -22.2 | · | · | · | |
| Kurs / FCF (TTM) | -321.25-Jahres-Durchschnitt ≈-50.3 | ≈-50.3 | · | · | |
| Kurs / Cashflow (TTM) | 107.25-Jahres-Durchschnitt ≈-125.0 | ≈-125.0 | 13.5 | Überbewertet | |
| EV / Revenue (EV / Umsatz) | 3.5 | · | · | · | |
| EV / FCF | -118.3 | · | · | · | |
| Kurs / Materieller Buchwert (MRQ) | 4.65-Jahres-Durchschnitt ≈40.2 | ≈40.2 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | NEO | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Bruttogewinnmarge (TTM) | 43.9%5-Jahres-Durchschnitt ≈40.8% | ≈40.8% | 32.6% | Spitzenklasse | |
| Betriebsgewinnmarge (TTM) | -8.9%5-Jahres-Durchschnitt ≈-20.7% | ≈-20.7% | 4.0% | Schwach | |
| EBITDA Margin (EBITDA-Marge) | -15.9%5-Jahres-Durchschnitt ≈-20.7% | ≈-20.7% | 4.5% | Schwach | |
| Vorgewinnmarge (TTM) | -7.1%5-Jahres-Durchschnitt ≈-15.6% | ≈-15.6% | 3.3% | Schwach | |
| Nettogewinnmarge (TTM) | -6.8%5-Jahres-Durchschnitt ≈-14.3% | ≈-14.3% | 2.4% | Schwach | |
| ROA | -7.2%5-Jahres-Durchschnitt ≈-5.1% | ≈-5.1% | 1.8% | Schwach | |
| ROE | -12.8%5-Jahres-Durchschnitt ≈-9.2% | ≈-9.2% | 3.3% | Schwach | |
| ROIC | -9.6%5-Jahres-Durchschnitt ≈-9.3% | ≈-9.3% | 5.0% | Schwach |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | NEO | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital (MRQ) | 0.5 | · | 0.3 | Hohe Verschuldung | |
| Liquiditätsgrad (MRQ) | 3.65-Jahres-Durchschnitt ≈5.4 | ≈5.4 | 1.5 | Starke Liquidität | |
| Quick Ratio | 3.65-Jahres-Durchschnitt ≈3.9 | ≈3.9 | 1.2 | Starke Liquidität | |
| Langfristige Schulden / Eigenkapital (MRQ) | 0.5 | · | 0.4 | Hohe Verschuldung |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | NEO | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 10.1%5-Jahres-Durchschnitt ≈10.4% | ≈10.4% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | 12.6%5-Jahres-Durchschnitt ≈11.2% | ≈11.2% | · | · | |
| Revenue CAGR 5Y (Umsatz CAGR 5J) | 10.3% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | NEO | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.55-Jahres-Durchschnitt ≈0.4 | ≈0.4 | 1.6 | Schwach | |
| Inventory Turnover (Lagerumschlag) | 14.95-Jahres-Durchschnitt ≈13.7 | ≈13.7 | · | · | |
| Receivables Turnover (Forderungsumschlag) | 4.75-Jahres-Durchschnitt ≈4.6 | ≈4.6 | 8.4 | Schwach | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$290.9K | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
55.4%
Nächster Bericht
Okt 26, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Jul 27, 2026 | $0.05 | $0.03 | 51.1% |
| 31. März 2026 | $0.01 | $0.01 | — | |
| 31. Dezember 2025 | $0.06 | $0.04 | 53.5% | |
| 30. September 2025 | $0.03 | $0.02 | 40.8% | |
| 30. Juni 2025 | $0.03 | $0.02 | 31.6% | |
| 31. März 2025 | $0.00 | $-0.01 | 100.0% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $727M | $661M | $592M | $510M | $484M | $444M | $409M | $277M | $240M | $232M | $5M | $5M | |
| Cost of Revenue | $413M | $370M | $347M | $322M | $297M | $259M | $212M | $149M | $138M | $134M | $56M | $46M | |
| Gross Profit | $314M | $290M | $245M | $188M | $187M | $186M | $197M | $127M | $102M | $98M | $44M | $41M | |
| R&D Expense | $37M | $31M | $27M | $30M | $22M | $8M | $8M | $3M | $4M | $5M | $4M | $3M | |
| SG&A Expense | $273M | $260M | $243M | $243M | $221M | $144M | $128M | $85M | $70M | $64M | $34M | $24M | |
| Operating Expenses | $430M | $382M | $352M | $346M | $306M | $200M | $184M | $117M | $99M | $96M | $49M | $38M | |
| Operating Income | $-116M | $-92M | $-108M | $-158M | $-119M | $-14M | $13M | $10M | $3M | $2M | $-6M | $2M | |
| Interest Expense | · | · | $7M | $8M | $8M | $7M | $4M | $6M | $6M | · | $854.0K | $985.0K | |
| Interest Income | $9M | $18M | $17M | $6M | $3M | · | · | · | · | · | · | · | |
| Other Non-op | $296.0K | $-379.0K | $644.0K | $-213.0K | $-499.0K | $8M | $-5M | $14.0K | $-12.0K | $0 | $2M | $56.0K | |
| Pretax Income | $-110M | $-81M | $-97M | $-159M | $-15M | $-14M | $4M | $4M | $-3M | $-8M | $-4M | $1M | |
| Income Tax | $-2M | $-2M | $-9M | $-15M | $-7M | $-18M | $-4M | $1M | $-2M | $-2M | $-2M | $157.0K | |
| Net Income | $-108M | $-79M | $-88M | $-144M | $-8M | $4M | $8M | $3M | $-396.0K | $-6M | $-3M | $1M | |
| EPS (Basic) | · | · | · | · | · | · | · | · | · | · | $-0.04 | $0.02 | |
| EPS (Diluted) | · | · | · | · | · | · | · | · | · | · | $-0.04 | $0.02 | |
| Shares (Basic) | 128,101,000 | 126,658,000 | 125,502,000 | 124,217,000 | 119,962,000 | 108,579,000 | 100,470,000 | 85,618,000 | 79,426,000 | 77,542,000 | 60,526,000 | 53,483,000 | |
| Shares (Diluted) | 128,101,000 | 126,658,000 | 125,502,000 | 124,217,000 | 119,962,000 | 111,794,000 | 103,615,000 | 91,568,000 | 79,426,000 | 77,542,000 | 60,526,000 | 56,016,000 | |
| EBITDA | $-116M | $-92M | $-108M | $-158M | $-119M | $-14M | $13M | · | $2M | · | $-6M | · |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $160M | $367M | $342M | $263M | $317M | $229M | $173M | $10M | $13M | $13M | $23M | $34M | |
| Receivables | $159M | $151M | $131M | $120M | $112M | $107M | $94M | $77M | $60M | $56M | $49M | $20M | |
| Inventory | $29M | $27M | $24M | $24M | $23M | $30M | $14M | $9M | $7M | $6M | $5M | $3M | |
| Prepaid Expense | $21M | $20M | $18M | $15M | $12M | $12M | $6M | $8M | $5M | $5M | $5M | $1M | |
| Other Current Assets | $7M | $12M | $8M | $8M | $8M | $5M | $3M | $561.0K | $1M | · | · | · | |
| Current Assets | $376M | $596M | $597M | $605M | $682M | $449M | $291M | $104M | $86M | $79M | $82M | $59M | |
| PP&E (Net) | $85M | $94M | $92M | $102M | $109M | $86M | $64M | $61M | $37M | $34M | $35M | $15M | |
| PP&E (Gross) | $294M | $284M | $250M | $234M | $219M | $179M | $133M | $111M | $77M | $61M | $61M | $35M | |
| Accum. Depreciation | $209M | $190M | $158M | $132M | $110M | $93M | $69M | $50M | $41M | $27M | $27M | $20M | |
| Goodwill | $524M | $523M | $523M | $523M | $527M | $211M | $199M | $198M | $147M | $147M | $147M | $3M | |
| Intangibles | $287M | $340M | $373M | $408M | $442M | $121M | $127M | $140M | $74M | $77M | $88M | $4M | |
| Other Non-current Assets | $9M | $6M | $5M | $5M | $7M | $5M | $3M | $3M | $891.0K | $174.0K | $129.0K | $141.0K | |
| Total Assets | $1.36B | $1.64B | $1.68B | $1.74B | $1.87B | $988M | $710M | $505M | $344M | $337M | $351M | $81M | |
| Accounts Payable | $23M | $22M | $20M | $21M | $18M | $25M | $20M | $18M | $10M | $17M | $12M | $6M | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | · | · | $1M | |
| Current Liabilities | $88M | $301M | $96M | $90M | $87M | $73M | $64M | $61M | $36M | $38M | $40M | $15M | |
| Capital Leases | $63M | $61M | $68M | $69M | $72M | $42M | $24M | $5M | $5M | $5M | $5M | $5M | |
| Deferred Tax | $18M | $22M | $24M | $35M | $55M | $5M | $16M | $22M | $7M | · | $16M | $821.0K | |
| Other Non-current Liabilities | $12M | $12M | $13M | $13M | $14M | $4M | $4M | $3M | $283.0K | · | · | · | |
| Total Liabilities | $523M | $736M | $740M | $742M | $762M | $294M | $202M | $185M | $140M | $151M | $113M | $21M | |
| Long-term Debt | $342M | $541M | $538M | · | · | · | · | $102M | $97M | $98M | $55M | · | |
| Total Debt | $342M | $541M | · | · | · | $0 | · | · | $95M | · | $53M | · | |
| Common Stock | · | · | · | · | · | · | · | · | · | · | · | $60.0K | |
| Retained Earnings | $-434M | $-326M | $-247M | $-159M | $-15M | $-7M | $-11M | $-19M | $-58M | $-52M | $-22M | $-19M | |
| Treasury Stock | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| AOCI | $4.0K | $-206.0K | $-2M | $-4M | $-638.0K | $10.0K | $-2M | $-579.0K | $274.0K | · | · | · | |
| Stockholders' Equity | $837M | $902M | $942M | $998M | $1.11B | $694M | $507M | $320M | $172M | $162M | $209M | $60M | |
| Liabilities + Equity | $1.36B | $1.64B | $1.68B | $1.74B | $1.87B | $988M | $710M | $505M | $344M | $337M | $351M | $81M | |
| Shares Outstanding | 128,989,152 | 128,145,333 | 127,369,142 | 126,913,992 | 124,107,500 | 112,075,474 | 104,781,236 | 94,465,440 | 80,462,574 | 78,571,158 | 75,820,307 | 60,242,818 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | $26M | $20M | $16M | $16M | $16M | $7M | $5M | |
| Stock-based Comp | $41M | $33M | $25M | $25M | $22M | $10M | $10M | $7M | $6M | $5M | $3M | $641.0K | |
| Deferred Tax | $-3M | $-3M | $-10M | $-15M | $-7M | $-18M | $-4M | $2M | $-2M | $-2M | $-2M | · | |
| Amort. of Intangibles | $32M | $33M | $35M | $34M | $23M | $10M | $10M | $6M | $7M | $7M | $412.0K | $295.0K | |
| Restructuring | $0 | $7M | $11M | $5M | $0 | $0 | · | · | · | · | · | · | |
| Operating Cash Flow | $5M | $7M | $-2M | $-66M | $-27M | $1M | $23M | $45M | $18M | $21M | $6M | $9M | |
| CapEx | $27M | $41M | $29M | $31M | $64M | $29M | $20M | $14M | $14M | $8M | $2M | $4M | |
| Investing Cash Flow | $-12M | $13M | $77M | $517.0K | $-632M | $-159M | $-20M | $-140M | $-14M | · | · | · | |
| Stock Issued | $962.0K | $5M | $5M | $13M | $15M | $20M | $11M | $9M | $3M | · | · | $34M | |
| Net Stock Activity | $962.0K | $5M | $5M | $13M | $15M | $20M | $11M | · | · | · | · | · | |
| Financing Cash Flow | $-200M | $5M | $5M | $12M | $725M | $236M | $159M | $92M | $-4M | · | · | · | |
| Net Change in Cash | · | · | · | · | · | $78M | $163M | $-3M | $296.0K | $-11M | $-10M | $29M | |
| Taxes Paid | $515.0K | $207.0K | $175.0K | $180.0K | $148.0K | $246.0K | $319.0K | $-31.0K | $284.0K | $290.0K | · | · | |
| Free Cash Flow | $-22M | $-34M | $-31M | $-97M | $-91M | $-28M | $3M | · | $4M | · | $4M | · | |
| Levered FCF | · | · | $-37M | $-98M | $-94M | $-26M | $-5M | · | · | · | $4M | · |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 43.2% | 43.9% | 41.3% | 36.9% | 38.6% | 41.8% | 48.1% | · | · | · | 875.1% | · | |
| Operating Margin | -15.9% | -13.9% | -18.2% | -30.9% | -24.5% | -3.1% | 3.2% | · | · | · | -112.7% | · | |
| Net Margin | -14.8% | -11.9% | -14.9% | -28.3% | -1.7% | 0.94% | 2.0% | · | · | · | -50.7% | · | |
| Pretax Margin | -15.2% | -12.2% | -16.4% | -31.3% | -3.1% | -3.2% | 0.89% | · | · | · | -89.8% | · | |
| EBITDA Margin | -15.9% | -13.9% | -18.2% | -30.9% | -24.5% | -3.1% | 3.2% | · | · | · | -112.7% | · | |
| ROA | -7.2% | -4.7% | -5.1% | -8.0% | -0.58% | 0.49% | 1.3% | · | -0.25% | · | -1.1% | · | |
| ROE | -12.8% | -8.7% | -9.3% | -14.3% | -0.74% | 0.61% | 1.6% | · | -0.50% | · | -1.9% | · | |
| ROIC | -9.6% | -6.2% | -10.4% | -14.3% | -5.9% | 0.60% | 5.6% | · | 0.21% | · | -1.2% | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.3 | 2.0 | 6.2 | 6.7 | 7.8 | 6.1 | 4.5 | · | 2.4 | · | 2.5 | · | |
| Quick Ratio | 3.6 | 1.7 | 4.9 | 4.3 | 4.9 | 4.6 | 4.2 | · | 2.1 | · | 1.8 | · | |
| Debt / Equity | 0.4 | 0.6 | · | · | · | 0.0 | · | · | 0.5 | · | 0.3 | · | |
| LT Debt / Equity | 0.4 | 0.4 | · | · | · | · | · | · | 0.5 | · | 0.2 | · | |
| Interest Coverage | · | · | -15.6 | -104.7 | -23.4 | -2.0 | 3.5 | · | · | · | -6.6 | · |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.4 | 0.3 | 0.3 | 0.3 | 0.5 | 0.7 | · | · | · | 0.0 | · | |
| Inventory Turnover | 14.9 | 14.6 | 14.3 | 13.5 | 11.2 | 11.8 | 18.4 | · | 20.1 | · | 14.5 | · | |
| Receivables Turnover | 4.7 | 4.7 | 4.7 | 4.4 | 4.4 | 4.4 | 4.8 | · | · | · | 0.1 | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $6.53 | $7.08 | $7.42 | $8.04 | $9.89 | $6.63 | $5.37 | · | $2.15 | · | $2.76 | · | |
| Revenue / Share | $5.68 | $5.22 | $4.71 | $4.10 | $4.04 | $3.98 | $3.95 | · | · | · | $0.08 | · | |
| Cash Flow / Share | $0.04 | $0.06 | $-0.02 | $-0.53 | $-0.22 | $0.01 | $0.23 | · | $0.23 | · | $0.11 | · | |
| Cash / Share | $1.25 | $2.88 | $2.70 | $2.12 | $2.83 | $2.18 | $1.83 | · | $0.16 | · | $0.31 | · | |
| EPS (TTM) | $-0.24 | $-0.24 | $-0.24 | $-0.24 | $-0.24 | $-0.24 | $-0.24 | $-0.24 | $-0.24 | $-0.24 | $-0.04 | $0.02 |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 10.1% | 11.7% | 16.1% | 5.2% | 9.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 12.6% | 10.9% | 10.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 10.3% | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $727M | $661M | $592M | $510M | $484M | $444M | $409M | $277M | $240M | $232M | $5M | $5M | |
| Net Income TTM | $-108M | $-79M | $-88M | $-144M | $-8M | $4M | $8M | $3M | $-396.0K | $-6M | $-3M | $1M | |
| Market Cap | $1.51B | $2.10B | $2.05B | $1.15B | $3.82B | $5.64B | $2.76B | · | $713M | · | $597M | · | |
| Enterprise Value | $1.69B | $2.27B | · | · | · | $5.41B | · | · | $795M | · | $626M | · | |
| P/E | -49.0 | -68.7 | -67.4 | -38.5 | -142.2 | -224.3 | -121.9 | -52.5 | -36.9 | -35.7 | -196.8 | 208.5 | |
| P/S | 2.1 | 3.2 | 3.5 | 2.2 | 7.9 | 12.7 | 6.8 | · | 3.0 | · | 119.3 | · | |
| P/B | 1.8 | 2.3 | 2.2 | 1.1 | 3.5 | 8.1 | 5.4 | · | 4.1 | · | 2.8 | · | |
| P / Tangible Book | 58.7 | 52.6 | 45.0 | 17.1 | 27.5 | 15.6 | · | · | · | · | · | · | |
| P / Cash Flow | 288.1 | 298.9 | -1051.4 | -17.4 | -143.1 | 3864.0 | 118.2 | · | 39.5 | · | 93.3 | · | |
| P / FCF | -69.2 | -61.7 | -66.9 | -11.8 | -42.1 | -204.1 | 827.3 | · | 164.0 | · | 142.8 | · | |
| EV / EBITDA | -14.6 | -24.7 | · | · | · | -386.8 | · | · | 342.1 | · | -111.1 | · | |
| EV / FCF | -77.6 | -66.8 | · | · | · | -195.9 | · | · | 182.9 | · | 149.9 | · | |
| EV / Revenue | 2.3 | 3.4 | · | · | · | 12.2 | · | · | 3.3 | · | 125.2 | · | |
| Earnings Yield | -2.0% | -1.5% | -1.5% | -2.6% | -0.70% | -0.45% | -0.82% | -1.9% | -2.7% | -2.8% | -0.51% | 0.48% |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $202M | $187M | $190M | $188M | $181M | $168M | $172M | $168M | $165M | $156M | $156M | $152M | $147M | $137M | $139M | $129M | |
| Cost of Revenue | $110M | $106M | $107M | $107M | $104M | $95M | $95M | $93M | $92M | $91M | $88M | $90M | $87M | $82M | $82M | $80M | |
| Gross Profit | $92M | $81M | $83M | $80M | $77M | $73M | $77M | $75M | $72M | $65M | $68M | $62M | $60M | $55M | $57M | $49M | |
| R&D Expense | $11M | $10M | $9M | $9M | $9M | $10M | $8M | $8M | $8M | $8M | $7M | $5M | $8M | $7M | $7M | $7M | |
| SG&A Expense | $64M | $66M | $64M | $70M | $72M | $68M | $64M | $67M | $63M | $66M | $60M | $61M | $60M | $62M | $55M | $64M | |
| Operating Expenses | $102M | $99M | $97M | $107M | $125M | $101M | $96M | $96M | $94M | $96M | $86M | $87M | $90M | $90M | $83M | $88M | |
| Operating Income | $-10M | $-18M | $-13M | $-27M | $-48M | $-28M | $-18M | $-21M | $-22M | $-31M | $-19M | $-24M | $-30M | $-35M | $-26M | $-40M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $2M | · | $-3M | $-3M | $2M | · | $139.0K | |
| Interest Income | $1M | $1M | $2M | $2M | $2M | $4M | $4M | $5M | $5M | $5M | $5M | $5M | $4M | $3M | · | · | |
| Other Non-op | $-17.0K | $-12.0K | $84.0K | $-335.0K | $482.0K | $65.0K | $-431.0K | $317.0K | $-2.0K | $-263.0K | $124.0K | $-96.0K | $730.0K | $-114.0K | $-1.0K | $25.0K | |
| Pretax Income | $2M | $-18M | $-12M | $-26M | $-46M | $-26M | $-16M | $-18M | $-19M | $-28M | $-15M | $-21M | $-27M | $-34M | $-26M | $-40M | |
| Income Tax | $-412.0K | $-472.0K | $-3M | $740.0K | $-724.0K | $266.0K | $-804.0K | $-150.0K | $-375.0K | $-620.0K | $-960.0K | $-3M | $-2M | $-3M | $-3M | $-3M | |
| Net Income | $2M | $-17M | $-10M | $-27M | $-45M | $-26M | $-15M | $-18M | $-19M | $-27M | $-14M | $-19M | $-24M | $-31M | $-23M | $-37M | |
| Shares (Basic) | 129,628,000 | 129,166,000 | · | 128,415,000 | 127,949,000 | 127,376,000 | · | 126,953,000 | 126,405,000 | 126,111,000 | · | 125,687,000 | 125,356,000 | 125,026,000 | · | 124,425,000 | |
| Shares (Diluted) | 130,831,000 | 129,166,000 | · | 128,415,000 | 127,949,000 | 127,376,000 | · | 126,953,000 | 126,405,000 | 126,111,000 | · | 125,687,000 | 125,356,000 | 125,026,000 | · | 124,425,000 | |
| EBITDA | $-10M | $-18M | · | $-27M | $-48M | $-28M | · | $-21M | $-22M | $-31M | · | $-24M | $-30M | $-35M | · | $-40M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $146M | $146M | $160M | $164M | $155M | $346M | $367M | $362M | $355M | $332M | · | $306M | $289M | $276M | · | $266M | |
| Receivables | $175M | $167M | $159M | $155M | $153M | $151M | $151M | $151M | $147M | $140M | · | $133M | $125M | $119M | · | $112M | |
| Inventory | $27M | $30M | $29M | $28M | $34M | $30M | $27M | $24M | $23M | $20M | · | $24M | $25M | $24M | · | $24M | |
| Prepaid Expense | $24M | $24M | $21M | $22M | $23M | $23M | $20M | $18M | $17M | $19M | · | $19M | $17M | $16M | · | $17M | |
| Other Current Assets | $10M | $7M | $7M | $11M | $10M | $12M | $12M | $8M | $9M | $9M | · | $9M | $8M | $8M | · | $8M | |
| Current Assets | $381M | $374M | $376M | $382M | $393M | $574M | $596M | $590M | $584M | $574M | · | $587M | $585M | $585M | · | $603M | |
| PP&E (Net) | $81M | $84M | $85M | $85M | $85M | $90M | $94M | $93M | $92M | $88M | · | $95M | $100M | $103M | · | $107M | |
| PP&E (Gross) | · | · | $294M | · | · | · | $284M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $223M | $216M | $209M | $209M | $201M | $199M | $190M | $181M | $176M | $168M | · | $155M | $147M | $139M | · | $125M | |
| Goodwill | $524M | $524M | $524M | $524M | $524M | $523M | $523M | $523M | $523M | $523M | $523M | $523M | $523M | $523M | · | $523M | |
| Intangibles | $271M | $279M | $287M | $294M | $302M | $331M | $340M | $348M | $356M | $365M | · | $382M | $391M | $399M | · | $417M | |
| Other Non-current Assets | $9M | $10M | $9M | $8M | $7M | $6M | $6M | $6M | $4M | $4M | · | $5M | $5M | $5M | · | $7M | |
| Total Assets | $1.35B | $1.35B | $1.36B | $1.37B | $1.39B | $1.60B | $1.64B | $1.64B | $1.64B | $1.64B | · | $1.68B | $1.70B | $1.71B | · | $1.76B | |
| Accounts Payable | $21M | $26M | $23M | $23M | $27M | $16M | $22M | $17M | $17M | $18M | · | $17M | $18M | $23M | · | $14M | |
| Current Liabilities | $106M | $85M | $88M | $98M | $100M | $280M | $301M | $296M | $290M | $77M | · | $93M | $95M | $87M | · | $85M | |
| Capital Leases | $65M | $61M | $63M | $64M | $67M | $60M | $61M | $62M | $63M | $65M | · | $62M | $65M | $67M | · | $70M | |
| Deferred Tax | $17M | $17M | $18M | $21M | $20M | $21M | $22M | $23M | $23M | $23M | · | $25M | $29M | $32M | · | $38M | |
| Other Non-current Liabilities | $862.0K | $12M | $12M | $12M | $12M | $12M | $12M | $12M | $12M | $13M | · | $13M | $13M | $13M | · | $14M | |
| Total Liabilities | $567M | $518M | $523M | $536M | $540M | $713M | $736M | $733M | $727M | $717M | · | $731M | $739M | $735M | · | $743M | |
| Long-term Debt | · | · | $342M | · | · | · | $541M | · | · | · | · | · | · | · | · | · | |
| Total Debt | $374M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Retained Earnings | $-449M | $-451M | $-434M | $-424M | $-397M | $-352M | $-326M | $-310M | $-293M | $-274M | · | $-233M | $-214M | $-190M | · | $-136M | |
| Treasury Stock | $25M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| AOCI | $4.0K | $4.0K | $4.0K | $71.0K | $29.0K | $-56.0K | $-206.0K | $-643.0K | $-1M | $-1M | · | $-2M | $-3M | $-3M | · | $-5M | |
| Stockholders' Equity | $786M | $829M | $837M | $838M | $854M | $888M | $902M | $908M | $916M | $923M | $942M | $947M | $956M | $974M | $998M | $1.01B | |
| Liabilities + Equity | $1.35B | $1.35B | $1.36B | $1.37B | $1.39B | $1.60B | $1.64B | $1.64B | $1.64B | $1.64B | · | $1.68B | $1.70B | $1.71B | · | $1.76B | |
| Shares Outstanding | 127,917,946 | 129,653,642 | 128,145,333 | 128,885,101 | 128,681,713 | 128,356,327 | 128,145,333 | 128,061,944 | 127,851,113 | 127,434,786 | 127,369,142 | 127,261,476 | 127,144,418 | 127,200,491 | 126,913,992 | 126,562,037 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $8M | $10M | $8M | $10M | $12M | $11M | $8M | $0 | $9M | $8M | $7M | $0 | $6M | $5M | $5M | $4M | |
| Amort. of Intangibles | $8M | $8M | $8M | $8M | $8M | $8M | $8M | $8M | $8M | $8M | $9M | $9M | $9M | $9M | $9M | $8M | |
| Restructuring | · | · | · | · | · | · | · | · | · | $2M | $1M | $2M | $3M | $5M | · | $0 | |
| Operating Cash Flow | $20M | $-8M | $1M | $9M | $20M | $-25M | $10M | $9M | $14M | $-26M | $18M | $-5M | $-2M | $-13M | $-4M | $-16M | |
| CapEx | $8M | $5M | $8M | $8M | $6M | $4M | $12M | $11M | $13M | $6M | $7M | $4M | $7M | $10M | $5M | $8M | |
| Investing Cash Flow | $-8M | $-5M | $-6M | $-277.0K | $-9M | $4M | $-5M | $-4M | $7M | $15M | $17M | $21M | $15M | $24M | $-1M | $-4M | |
| Stock Issued | $2M | $-338.0K | $431.0K | $765.0K | $-1M | $949.0K | $687.0K | $1M | $2M | $816.0K | $1M | $2M | $93.0K | $1M | $2M | $3M | |
| Net Stock Activity | · | $-338.0K | · | · | · | $949.0K | · | · | · | $816.0K | · | · | · | $1M | · | · | |
| Financing Cash Flow | $-12M | $-338.0K | $431.0K | $765.0K | $-202M | $949.0K | $687.0K | $1M | $2M | $816.0K | $1M | $2M | $64.0K | $1M | $2M | $3M | |
| Net Change in Cash | · | · | · | $9M | · | · | · | $7M | $23M | $-11M | · | $17M | $13M | $12M | · | $-18M | |
| Taxes Paid | $711.0K | $0 | $57.0K | $0 | $458.0K | $0 | $-112.0K | $143.0K | $87.0K | $89.0K | $0 | $0 | $175.0K | $0 | $25.0K | $26.0K | |
| Free Cash Flow | · | $-13M | · | · | · | $-30M | · | · | · | $-32M | · | · | · | $-23M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-33M | · | · | · | · | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 45.6% | 43.3% | · | 42.8% | 42.6% | 43.6% | · | 44.6% | 44.1% | 41.9% | · | 41.0% | 40.8% | 40.0% | · | 38.0% | |
| Operating Margin | -4.9% | -9.8% | · | -14.4% | -26.3% | -16.6% | · | -12.6% | -13.3% | -19.6% | · | -15.9% | -20.3% | -25.6% | · | -30.7% | |
| Net Margin | 1.1% | -9.2% | · | -14.4% | -24.9% | -15.4% | · | -10.5% | -11.3% | -17.3% | · | -12.2% | -16.6% | -22.4% | · | -28.6% | |
| Pretax Margin | 0.91% | -9.4% | · | -14.1% | -25.3% | -15.3% | · | -10.6% | -11.6% | -17.7% | · | -14.1% | -18.1% | -24.6% | · | -30.8% | |
| EBITDA Margin | -4.9% | -9.8% | · | -14.4% | -26.3% | -16.6% | · | -12.6% | -13.3% | -19.6% | · | -15.9% | -20.3% | -25.6% | · | -30.7% | |
| ROA | 0.16% | -1.2% | · | -1.8% | -3.0% | -1.6% | · | -1.1% | -1.1% | -1.6% | · | -1.1% | -1.4% | -1.7% | · | -2.0% | |
| ROE | 0.27% | -2.0% | · | -3.1% | -5.1% | -2.9% | · | -1.9% | -2.0% | -2.9% | · | -1.9% | -2.4% | -3.0% | · | -3.4% | |
| ROIC | -1.0% | -2.1% | · | -3.3% | -5.5% | -3.2% | · | -2.3% | -2.4% | -3.2% | · | -2.2% | -2.9% | -3.3% | · | -3.6% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.6 | 4.4 | · | 3.9 | 3.9 | 2.1 | · | 2.0 | 2.0 | 7.5 | · | 6.3 | 6.2 | 6.8 | · | 7.1 | |
| Quick Ratio | 3.0 | 3.7 | · | 3.3 | 3.1 | 1.8 | · | 1.7 | 1.7 | 6.2 | · | 4.7 | 4.4 | 4.6 | · | 4.4 | |
| Debt / Equity | 0.5 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.5 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -18.1 | · | 8.5 | 11.8 | · | · | -284.2 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 3.6 | 3.6 | · | 4.1 | 3.6 | 3.8 | · | 3.8 | 3.8 | 4.1 | · | 3.7 | 3.7 | 3.4 | · | 3.5 | |
| Receivables Turnover | 1.2 | 1.2 | · | 1.2 | 1.2 | 1.2 | · | 1.2 | 1.2 | 1.2 | · | 1.2 | 1.2 | 1.2 | · | 1.2 |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $6.14 | $6.39 | · | $6.50 | $6.64 | $6.92 | · | $7.09 | $7.16 | $7.25 | · | $7.44 | $7.52 | $7.66 | · | $8.00 | |
| Revenue / Share | $1.54 | $1.45 | · | $1.46 | $1.42 | $1.32 | · | $1.32 | $1.30 | $1.24 | · | $1.21 | $1.17 | $1.10 | · | $1.03 | |
| Cash Flow / Share | · | $-0.06 | · | · | · | $-0.20 | · | · | · | $-0.21 | · | · | · | $-0.10 | · | · | |
| Cash / Share | $1.14 | $1.13 | · | $1.27 | $1.20 | $2.70 | · | $2.83 | $2.78 | $2.60 | · | $2.41 | $2.27 | $2.17 | · | $2.10 | |
| EPS (TTM) | $-0.24 | $-0.24 | · | $-0.24 | $-0.24 | $-0.24 | · | $-0.24 | $-0.24 | $-0.24 | · | $-0.24 | $-0.24 | $-0.24 | · | $-0.24 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $766M | $746M | · | $709M | $689M | $672M | · | $644M | $628M | $611M | · | $575M | $552M | $530M | · | $497M | |
| Net Income TTM | $-52M | $-99M | · | $-113M | $-104M | $-78M | · | $-78M | $-79M | $-84M | · | $-96M | $-115M | $-126M | · | $-163M | |
| Market Cap | $1.87B | $962M | · | $995M | $941M | $1.22B | · | $1.89B | $1.77B | $2.00B | · | $1.57B | $2.04B | $2.21B | · | $1.09B | |
| Enterprise Value | $2.10B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | -60.8 | -30.9 | · | -32.2 | -30.5 | -39.5 | · | -61.5 | -57.8 | -65.5 | · | -51.2 | -67.0 | -72.5 | · | -35.9 | |
| P/S | 2.4 | 1.3 | · | 1.4 | 1.4 | 1.8 | · | 2.9 | 2.8 | 3.3 | · | 2.7 | 3.7 | 4.2 | · | 2.2 | |
| P/B | 2.4 | 1.2 | · | 1.2 | 1.1 | 1.4 | · | 2.1 | 1.9 | 2.2 | · | 1.7 | 2.1 | 2.3 | · | 1.1 | |
| P / Tangible Book | · | 37.2 | · | 50.3 | 33.5 | 35.6 | · | 50.5 | 48.3 | 55.8 | · | 36.6 | 47.8 | 42.4 | · | 14.9 | |
| P / Cash Flow | · | -118.2 | · | · | · | -48.1 | · | · | · | -77.3 | · | · | · | -174.5 | · | · | |
| EV / Revenue | 2.7 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -1.6% | -3.2% | · | -3.1% | -3.3% | -2.5% | · | -1.6% | -1.7% | -1.5% | · | -1.9% | -1.5% | -1.4% | · | -2.8% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $727M | $661M | $592M | $510M | $484M |
| Bruttogewinnmarge % | 43.2% | 43.9% | 41.3% | 36.9% | 38.6% |
| Betriebsgewinnmarge % | -15.9% | -13.9% | -18.2% | -30.9% | -24.5% |
| Nettoergebnis | $-108M | $-79M | $-88M | $-144M | $-8M |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | 0.4 | 0.6 | · | · | · |
| Liquiditätsgrad | 4.3 | 2.0 | 6.2 | 6.7 | 7.8 |
| Quick Ratio | 3.6 | 1.7 | 4.9 | 4.3 | 4.9 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-22M | $-34M | $-31M | $-97M | $-91M |
Institutionelle Eigentümer (13F) 296 Einreicher · $2.4B gesamt · Stand 30. September 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
296
Gehaltener Wert
$2.4B
Neue Positionen
58
Geschlossene Positionen
38
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 58 (+9 vs. Vorquartal) | 38 (+2 vs. Vorquartal) | 100 (+22 vs. Vorquartal) | 61 (-22 vs. Vorquartal) | +19.6M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| BlackRock, Inc. | $304.469.400 | 20.868.362 | 12,94% | Aktien |
| First Light Asset Management, LLC | $179.158.241 | 12.279.523 | 7,61% | Aktien |
| VANGUARD GROUP INC | $162.621.455 | 13.828.355 | 6,91% | Aktien |
| FIRST TRUST ADVISORS LP | $147.552.477 | 10.113.261 | 6,27% | Aktien |
| Greenhouse Funds LLLP | $125.097.724 | 8.574.210 | 5,32% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $117.615.272 | 8.061.362 | 5,00% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $84.082.418 | 5.763.017 | 3,57% | Aktien |
| STATE STREET CORP | $78.257.609 | 5.363.784 | 3,33% | Aktien |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $73.501.000 | 5.037.787 | 3,12% | Aktien |
| BRAIDWELL LP | $71.756.567 | 4.918.202 | 3,05% | Aktien |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $61.886.083 | 4.342.883 | 2,63% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $50.558.727 | 3.465.300 | 2,15% | Kaufoption |
| GEODE CAPITAL MANAGEMENT, LLC | $50.025.999 | 3.428.123 | 2,13% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $44.930.518 | 3.079.542 | 1,91% | Aktien |
| TORONTO DOMINION BANK | $43.770.000 | 3.000.000 | 1,86% | Kaufoption |
| LOOMIS SAYLES & CO L P | $37.025.291 | 2.537.717 | 1,57% | Aktien |
| Driehaus Capital Management LLC | $36.604.049 | 2.508.845 | 1,56% | Aktien |
| BANK OF AMERICA CORP /DE/ | $35.546.038 | 2.436.329 | 1,51% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $35.003.708 | 2.399.411 | 1,49% | Aktien |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $34.896.129 | 2.391.784 | 1,48% | Aktien |
| AMERICAN CAPITAL MANAGEMENT INC | $32.648.145 | 2.237.707 | 1,39% | Aktien |
| UBS Group AG | $32.581.659 | 2.233.150 | 1,38% | Kaufoption |
| D. E. Shaw & Co., Inc. | $32.021.519 | 2.194.758 | 1,36% | Aktien |
| SAMLYN CAPITAL, LLC | $31.096.207 | 2.131.337 | 1,32% | Aktien |
| Aberdeen Group plc | $28.180.950 | 1.931.525 | 1,20% | Aktien |
| MORGAN STANLEY | $27.693.709 | 1.898.128 | 1,18% | Aktien |
| GOLDMAN SACHS GROUP INC | $22.859.028 | 1.566.760 | 0,97% | Aktien |
| NORTHERN TRUST CORP | $22.456.651 | 1.539.181 | 0,95% | Aktien |
| GLENMEDE TRUST CO NA | $22.141.579 | 1.517.586 | 0,94% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $17.689.018 | 1.212.407 | 0,75% | Aktien |
| SEGALL BRYANT & HAMILL, LLC | $15.850.518 | 1.086.396 | 0,67% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $12.685.640 | 869.475 | 0,54% | Aktien |
| AQR CAPITAL MANAGEMENT LLC | $12.149.312 | 832.715 | 0,52% | Aktien |
| Glenmede Investment Management, LP | $12.057.018 | 1.561.790 | 0,51% | Aktien |
| Connor, Clark & Lunn Investment Management Ltd. | $11.709.890 | 802.597 | 0,50% | Aktien |
| Bank of New York Mellon Corp | $10.743.609 | 736.368 | 0,46% | Aktien |
| CITIGROUP INC | $9.748.716 | 668.178 | 0,41% | Aktien |
| PRINCIPAL FINANCIAL GROUP INC | $9.189.162 | 629.826 | 0,39% | Aktien |
| HighMark Wealth Management LLC | $8.936.871 | 612.534 | 0,38% | Aktien |
| Invesco Ltd. | $8.754.555 | 600.038 | 0,37% | Aktien |
| UBS Group AG | $8.391.672 | 575.166 | 0,36% | Aktien |
| JPMORGAN CHASE & CO | $8.363.938 | 581.091 | 0,36% | Aktien |
| JUPITER ASSET MANAGEMENT LTD | $7.841.935 | 537.487 | 0,33% | Aktien |
| Public Sector Pension Investment Board | $6.526.545 | 447.330 | 0,28% | Aktien |
| Trexquant Investment LP | $6.358.074 | 435.783 | 0,27% | Aktien |
| Nuveen, LLC | $6.172.300 | 423.050 | 0,26% | Aktien |
| Granite Investment Partners, LLC | $5.181.507 | 355.141 | 0,22% | Aktien |
| AMERIPRISE FINANCIAL INC | $4.625.865 | 317.057 | 0,20% | Aktien |
| RHUMBLINE ADVISERS | $4.624.054 | 316.935 | 0,20% | Aktien |
| Legal & General Group Plc | $4.317.503 | 295.922 | 0,18% | Aktien |
Aktivisten & 5%+-Eigentümer 1 Beteiligung
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| IRS IDENTIFICATION NO. NeoGenomics, Inc. | 12. April 2007 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 52 Insider · 31 Führungskräfte · 23 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Anthony P. Zook | Chief Executive Officer | 1. April 2026 M | 133.111 | 0 | 0 | $0 |
| Christopher M Smith | Chief Executive Officer | 23. Februar 2025 M | 641.585 | 0 | 0 | $0 |
| Mark Mallon | Chief Executive Officer | 1. März 2022 A | 368.051 | 0 | 0 | $0 |
| Jeffrey Scott Sherman | Chief Financial Officer | 23. Februar 2026 M | 220.009 | 0 | 0 | $0 |
| William Bonello | Chief Financial Officer | 28. April 2022 M | 191.548 | 0 | 0 | $0 |
| Sharon Virag | Chief Financial Officer | 1. März 2019 A | 10.944 | 0 | 0 | $0 |
| Vishal Sikri | President Advanced Diagnostics | 23. Februar 2024 A | 127.716 | 0 | 0 | $0 |
| David Sholehvar | President, Clinical Services | 1. August 2022 A | 43.216 | 0 | 0 | $0 |
| George Cardoza | President & COO, Lab Ops | 2. März 2022 F | 244.157 | 0 | 0 | $0 |
| Gina M Wallar | President, Pharma Services | 1. März 2022 A | 33.443 | 0 | 0 | $0 |
| Clive Morris | President of Inivata | 30. Dezember 2021 A | 41.280 | 0 | 0 | $0 |
| Robert J. Shovlin | President, Clinical Services | 25. Mai 2021 M | 150.101 | 0 | 0 | $0 |
| Warren Stone | Pres & Chief Operating Officer | 21. August 2026 M | 181.078 | 0 | 1 | $-276.600 |
| Alicia C Olivo | EVP, GC & Business Development | 1. September 2026 F | 90.875 | 0 | 2 | $-300.172 |
| Greg D Aunan | Chief Accounting Officer | 4. August 2026 S | 5.153 | 0 | 1 | $-321.400 |
| Melody Harris | Chf Ops Off, Pres, Informatics | 23. Februar 2025 M | 109.755 | 0 | 0 | $0 |
| Shashikant Kulkarni | Chief Scientific Officer | 1. April 2023 F | 82.673 | 0 | 0 | $0 |
| Cynthia J Dieter | Chief Accounting Officer | 2. März 2023 F | 29.765 | 0 | 0 | $0 |
| Douglas Matthew Brown | Chief Strategy Officer | 1. April 2022 A | 158.684 | 0 | 0 | $0 |
| Halley E Gilbert | Chief Legal Officer | 1. März 2022 A | 147.396 | 0 | 0 | $0 |
| Kathryn B Mckenzie | Chief Sustainability/Risk Ofcr | 11. Januar 2022 M | 49.361 | 0 | 0 | $0 |
| Jennifer Balliet | VP and Chief Culture Officer | 30. Dezember 2021 A | 48.615 | 0 | 0 | $0 |
| Lawrence Martin Weiss | Chief Medical Officer | 22. April 2021 M | 130.847 | 0 | 0 | $0 |
| Denise E Pedulla | General Counsel | 2. März 2021 A | 60.643 | 0 | 0 | $0 |
| Steven G. Brodie | VP - Pharma Operations | 22. Oktober 2018 M | 45.953 | 0 | 0 | $0 |
| Steven A Ross | CIO | 10. Mai 2018 X | 4.500 | 0 | 0 | $0 |
| Maher Albitar | Chief Medical Officer | 25. Mai 2017 A | 60.692 | 0 | 0 | $0 |
| Mark Alan Machulcz | Vice President of Operations | 28. Januar 2016 A | · | 0 | 0 | $0 |
| Robert H. Horel | Vice President GM PathLogic | 29. Dezember 2015 X | 51.218 | 0 | 0 | $0 |
| Robert P Gasparini | Chief Science Officer | 22. Mai 2014 X | 8.439 | 0 | 0 | $0 |
| Mark W Smits | Chief Commercial Officer | 18. Mai 2011 M | 0 | 0 | 0 | $0 |
| Carolyn S Starrett | Direktor | 23. Juni 2026 A | · | 0 | 0 | $0 |
| Lynn A. Tetrault | Direktor | 15. Juni 2026 S | 86.115 | 0 | 2 | $-118.824 |
| Marjorie C Green | Direktor | 1. Juni 2026 A | 22.964 | 0 | 0 | $0 |
| Neil Gunn | Direktor | 1. Juni 2026 A | 51.177 | 0 | 0 | $0 |
| Michael Aaron Kelly | Direktor | 1. Juni 2026 A | 67.086 | 0 | 0 | $0 |
| David Brian Perez | Direktor | 1. Juni 2026 A | 56.967 | 0 | 0 | $0 |
| John P. Kenny | Direktor | 1. Juni 2026 A | 5.893 | 0 | 0 | $0 |
| Stephen M Kanovsky | Direktor | 1. Juni 2026 A | 75.421 | 0 | 0 | $0 |
| Felicia Williams | Direktor | 1. Juni 2026 A | 30.237 | 0 | 0 | $0 |
| Elizabeth Floegel | Direktor | 1. Juni 2025 A | 23.590 | 0 | 0 | $0 |
| Alison L. Hannah | Direktor | 1. Juni 2025 M | 131.023 | 0 | 0 | $0 |
| Bruce K Crowther | Direktor | 10. August 2023 A | 65.120 | 0 | 0 | $0 |
| Rachel A Stahler | Direktor | 10. Juni 2022 A | 21.335 | 0 | 0 | $0 |
| David Daly | Direktor | 10. Juni 2022 A | 17.179 | 0 | 0 | $0 |
| Kevin C Johnson | Direktor | 22. Dezember 2021 M | 37.398 | 0 | 0 | $0 |
| Douglas M Van Oort | Direktor | 1. August 2021 F | 2.468.797 | 0 | 0 | $0 |
| Steven C Jones | Direktor | 7. Januar 2021 M | 90.218 | 0 | 0 | $0 |
| Raymond R Hipp | Direktor | 16. November 2020 S | 66.800 | 0 | 0 | $0 |
| William J Robison | Direktor | 25. Mai 2017 A | 183.348 | 0 | 0 | $0 |
| Michael T Dent | Direktor | 4. Dezember 2014 S | 1.384.150 | 0 | 0 | $0 |
| Peter M Peterson | Direktor | 5. Juni 2012 A | 34.500 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 52 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| PTH · Invesco Exchange-Traded Fund Trust | 1,36% | 220.212 SH | 2. Oktober 2026 | Täglich |
| PSCH · Invesco Exchange-Traded Fund Trust … | 1,25% | 122.042 SH | 2. Oktober 2026 | Täglich |
| XSMO · Invesco Exchange-Traded Fund Trust | 0,81% | 1.312.429 SH | 2. Oktober 2026 | Täglich |
| FYC · First Trust Exchange-Traded AlphaDE… | 0,71% | 601.468 NS | 31. Juli 2026 | N-PORT |
| DWAS · Invesco Exchange-Traded Fund Trust … | 0,38% | 86.758 SH | 2. Oktober 2026 | Täglich |
| IHF · iShares Trust | 0,34% | 250.331 SH | 11. September 2026 | Täglich |
| FYX · First Trust Exchange-Traded AlphaDE… | 0,27% | 239.159 NS | 31. Juli 2026 | N-PORT |
| QVMS · Invesco Exchange-Traded Fund Trust … | 0,15% | 19.929 SH | 2. Oktober 2026 | Täglich |
| NUSC · Nushares ETF Trust | 0,15% | 126.293 NS | 31. Juli 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,14% | 54.487 NS | 31. Juli 2026 | N-PORT |
| VIOG · VANGUARD ADMIRAL FUNDS | 0,12% | 89.895 SH | 19. August 2026 | Täglich |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,12% | 176.579 SH | 2. Oktober 2026 | Täglich |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,11% | 104.297 SH | 19. August 2026 | Täglich |
| VIOO · VANGUARD ADMIRAL FUNDS | 0,10% | 455.144 SH | 19. August 2026 | Täglich |
| ESML · iShares Trust | 0,09% | 146.435 SH | 11. September 2026 | Täglich |
| VIOV · VANGUARD ADMIRAL FUNDS | 0,09% | 116.046 SH | 19. August 2026 | Täglich |
| JPSE · J.P. Morgan Exchange-Traded Fund Tr… | 0,09% | 33.444 NS | 31. Juli 2026 | N-PORT |
| IWM · iShares Trust | 0,08% | 3.367.792 SH | 11. September 2026 | Täglich |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,08% | 34.215 NS | 31. Juli 2026 | N-PORT |
| ISCG · iShares Trust | 0,07% | 40.558 SH | 11. September 2026 | Täglich |
| RSSL · Global X Funds | 0,06% | 63.019 NS | 31. Juli 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,06% | 757.699 SH | 19. August 2026 | Täglich |
| SMDX · Tidal Trust III | 0,05% | 4.493 NS | 31. Juli 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,05% | 1.728.845 SH | 19. August 2026 | Täglich |
| RWJ · Invesco Exchange-Traded Fund Trust … | 0,05% | 55.092 SH | 2. Oktober 2026 | Täglich |
| DFAS · Dimensional ETF Trust | 0,04% | 358.850 NS | 31. Juli 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,03% | 388.986 SH | 19. August 2026 | Täglich |
| WSML · iShares Trust | 0,03% | 10.624 SH | 11. September 2026 | Täglich |
| FHLC · FIDELITY COVINGTON TRUST | 0,03% | 62.331 NS | 31. Juli 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,02% | 8.379 NS | 31. Juli 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,02% | 1.492.431 SH | 19. August 2026 | Täglich |
| VB · VANGUARD INDEX FUNDS | 0,02% | 2.990.594 SH | 19. August 2026 | Täglich |
| IWO · iShares Trust | 0,01% | 115.979 SH | 11. September 2026 | Täglich |
| DFAC · Dimensional ETF Trust | 0,01% | 344.253 NS | 31. Juli 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0,01% | 15.340 NS | 31. Juli 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,01% | 12.627 SH | 19. August 2026 | Täglich |
| DCOR · Dimensional ETF Trust | 0,01% | 14.534 NS | 31. Juli 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,00% | 30.125 NS | 31. Juli 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,00% | 47.070 NS | 31. Juli 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 172.474 SH | 11. September 2026 | Täglich |
| TILT · FlexShares Trust | 0,00% | 4.536 NS | 31. Juli 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 35.356 SH | 10. September 2026 | Täglich |
| IXUS · iShares Trust | 0,00% | 56.854 SH | 11. September 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 4.136.535 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 10.236 SH | 19. August 2026 | Täglich |
| IJR · iShares Trust | · | 7.951.677 SH | 10. September 2026 | Täglich |
| IJT · iShares Trust | · | 716.232 SH | 9. September 2026 | Täglich |
| IJS · iShares Trust | · | 490.259 SH | 8. September 2026 | Täglich |
| IWN · iShares Trust | · | 1.129.992 SH | 11. September 2026 | Täglich |
| XJR · iShares Trust | · | 18.003 SH | 31. August 2026 | Täglich |
| ISCB · iShares Trust | · | 5.811 SH | 11. September 2026 | Täglich |
| SMLF · iShares Trust | · | 45.624 SH | 11. September 2026 | Täglich |
NEO Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 16 Analysten
KAUF
Median-Ziel
$19.00
+2,9%
4 25,0%
Starker Kauf
7 43,8%
Kauf
5 31,2%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
9 Analysten · 2026-10-02Mittelwert-Ziel $19.72 +6,8%
Jetzt
Aktueller Preis $18.47
Tief$16.00
Mittelwert$19.72
Hoch$35.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| NEO | $1.51B | -49.0 | 10.1% | -14.8% | -12.8% | 43.2% |
| OPCH | $5.00B | 25.1 | 13.0% | 3.7% | 15.4% | 19.3% |
| AVAH | $1.70B | 7.7 | 20.2% | 9.2% | 246.6% | 33.3% |
| GRDN | · | · | 17.9% | 3.4% | 24.8% | 20.2% |
| PRVA | $2.93B | 131.7 | 22.3% | 1.1% | 3.3% | · |
| MD | $1.77B | 11.0 | -4.9% | 8.6% | 20.3% | · |
| ADUS | · | 20.6 | 23.2% | · | · | · |
| WGS | · | · | · | · | · | · |
| ASTH | $1.21B | 53.9 | 56.4% | 0.71% | 3.0% | · |
| AMN | $606M | -6.4 | -8.5% | -3.5% | -15.3% | 28.3% |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Jul 28, 2026